Search research articles
Contact Us
Filters
Showing results (31-40 of 140) with videos related to
Page
of 14
Sort By:
Future Oncology (London, England)
|
July 14, 2025
Matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPC
Andrew J Armstrong, Bhavik J Pandya, Hemant Singh Bhadauria, et al.
Seminars in Nuclear Medicine
|
July 3, 2023
Role of FDG PET/CT in Management of Patients with Prostate Cancer
Duncan E K Sutherland, Arun A Azad, Declan G Murphy, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 13, 2025
Safety and Efficacy of 20 Cycles of [<sup>177</sup>Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Kerry E Jewell, James P Buteau, Elizabeth Medhurst, et al.
European Urology Oncology
|
December 6, 2023
Cost Effectiveness of Systemic Treatment Intensification for Metastatic Hormone-sensitive Prostate Cancer: Is Triplet Therapy Cost Effective?
Niranjan J Sathianathen, Nathan Lawrentschuk, Badrinath Konety, et al.
Urologic Oncology
|
November 21, 2022
Emergence of triplet therapy for metastatic castration-sensitive prostate cancer: An updated systematic review and network meta-analysis
Niranjan J Sathianathen, Henry Y C Pan, Nathan Lawrentschuk, et al.
Nature Reviews. Urology
|
December 12, 2022
Combination treatment in metastatic prostate cancer: is the bar too high or have we fallen short?
Kenneth Chen, Jonathan O'Brien, Aoife McVey, et al.
Investigational New Drugs
|
April 27, 2025
Phase 1 study of HP518, a PROTAC AR degrader in patients with mCRPC: results on safety, pharmacokinetics, and anti-tumor activity
Arun A Azad, Howard Gurney, Craig Underhill, et al.
BJU International
|
July 27, 2023
Is genetic testing coming of age in advanced prostate cancer?
Kenneth Chen, Sean Ong, Kandarpa Vasundhara, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
June 4, 2026
Exposure-safety analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial
Yibo Wang, Mark Hadigol, Victor Ruberio Lincha, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 20, 2025
Clinical Trial Protocol for LuCAB: A Phase I-II Trial Evaluating Cabazitaxel in Combination with [<sup>177</sup>Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer
Louise Kostos, James P Buteau, Grace Kong, et al.
Page
of 14
Search research articles
Search
Showing results (31-40 of 140) with videos related to
Sort By:
Page
of 14
Future Oncology (London, England)
|
July 14, 2025
Matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPC
Andrew J Armstrong, Bhavik J Pandya, Hemant Singh Bhadauria, et al.
Seminars in Nuclear Medicine
|
July 3, 2023
Role of FDG PET/CT in Management of Patients with Prostate Cancer
Duncan E K Sutherland, Arun A Azad, Declan G Murphy, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 13, 2025
Safety and Efficacy of 20 Cycles of [<sup>177</sup>Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Kerry E Jewell, James P Buteau, Elizabeth Medhurst, et al.
European Urology Oncology
|
December 6, 2023
Cost Effectiveness of Systemic Treatment Intensification for Metastatic Hormone-sensitive Prostate Cancer: Is Triplet Therapy Cost Effective?
Niranjan J Sathianathen, Nathan Lawrentschuk, Badrinath Konety, et al.
Urologic Oncology
|
November 21, 2022
Emergence of triplet therapy for metastatic castration-sensitive prostate cancer: An updated systematic review and network meta-analysis
Niranjan J Sathianathen, Henry Y C Pan, Nathan Lawrentschuk, et al.
Nature Reviews. Urology
|
December 12, 2022
Combination treatment in metastatic prostate cancer: is the bar too high or have we fallen short?
Kenneth Chen, Jonathan O'Brien, Aoife McVey, et al.
Investigational New Drugs
|
April 27, 2025
Phase 1 study of HP518, a PROTAC AR degrader in patients with mCRPC: results on safety, pharmacokinetics, and anti-tumor activity
Arun A Azad, Howard Gurney, Craig Underhill, et al.
BJU International
|
July 27, 2023
Is genetic testing coming of age in advanced prostate cancer?
Kenneth Chen, Sean Ong, Kandarpa Vasundhara, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
June 4, 2026
Exposure-safety analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial
Yibo Wang, Mark Hadigol, Victor Ruberio Lincha, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 20, 2025
Clinical Trial Protocol for LuCAB: A Phase I-II Trial Evaluating Cabazitaxel in Combination with [<sup>177</sup>Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer
Louise Kostos, James P Buteau, Grace Kong, et al.
Page
of 14